Phosphate replacement mrna cap analogs
US-2018305393-A1 · Oct 25, 2018 · US
Phosphate replacement MRNA cap analogs
US10570388B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10570388-B2 |
| Application number | US-201816008658-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 14, 2018 |
| Priority date | Oct 16, 2015 |
| Publication date | Feb 25, 2020 |
| Grant date | Feb 25, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the cap analogs.
First claim
Opening claim text (preview).
What is claimed is: 1. An RNA molecule having a 5′ end comprising a compound of formula (III): wherein B 1 is R a , R b , and R c are H; R 1 is CH 3 ; B 2 is R d , R e , and R f are H; X 1 is N or N + (CH 3 ); X 2 is O; R 20 , R 21 , R 22 , and R 23 are H; R 27 and R 28 are OH; R 2 is OR 3 ; R 3 is H or CH 3 ; and Y 2 is wherein indicates an attachment point. 2. The RNA molecule of claim 1 , wherein X 1 is N. 3. The RNA molecule of claim 1 , wherein R 3 is CH 3 . 4. The RNA molecule of claim 1 , wherein X 1 is N + (CH 3 ). 5. The RNA molecule of claim 1 , wherein R 3 is H. 6. The RNA molecule of claim 1 , wherein R 3 is H and X 1 is N. 7. The RNA molecule of claim 1 , wherein R 3 is H and X 1 is N + (CH 3 ). 8. The RNA molecule of claim 1 , wherein R 3 is CH 3 and X 1 is N + (CH 3 ). 9. The RNA molecule of claim 1 , having a 5′ end comprising wherein indicates the attachment point. 10. The RNA molecule of claim 9 , wherein X 1 is N. 11. The RNA molecule of claim 9 , wherein R 3 is CH 3 . 12. The RNA molecule of claim 9 , wherein X 1 is N + (CH 3 ). 13. The RNA molecule of claim 9 , wherein R 3 is H. 14. The RNA molecule of claim 9 , wherein R 3 is H and X 1 is N. 15. The RNA molecule of claim 9 , wherein R 3 is H and X 1 is N + (CH 3 ). 16. The RNA molecule of claim 9 , wherein R 3 is CH 3 and X 1 is N + (CH 3 ). 17. The RNA molecule of claim 1 , having a 5′ end comprising wherein indicates the attachment point.
Assignees
Inventors
Classifications
Methylphosphonates · CPC title
with ribosyl as saccharide radical · CPC title
- C07D473/18Primary
one oxygen and one nitrogen atom, e.g. guanine · CPC title
attached in position 6, e.g. adenine · CPC title
with an inverted bond, e.g. a cap structure · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10570388B2 cover?
- The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the cap analogs.
- Who is the assignee on this patent?
- Modernatx Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D473/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).